Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
20多個州的總檢察長對暫停墮胎藥物批准敲響警鐘：未來有 “毀滅性風險”
- In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating risks to millions of people," including those in states where abortion remains legal.
- The attorneys general, in their filing, called on the U.S. 5th Circuit Court of Appeals to keep mifepristone on the market.
- Last week Friday, a U.S. judge suspended the FDA's approval of mifepristone, an abortion pill to terminate a pregnancy through ten weeks gestation.
- But he put his decision on hold for one week to give the Biden administration time to appeal.
- Also Read - Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension.
- Kacsmaryk's ruling will take effect at 12 a.m. CT on Saturday if the 5th Circuit does not halt it.
- Citing the filing, CNBC reported that attorneys general and the District of Columbia condemned Kacsmaryk's ruling as "legally erroneous" and warned it would undermine the FDA's approval process.
- The attorneys general argued that Kacsmaryk's order would "eviscerate the sovereign decisions" made by the states to protect access to abortion when last year, the Supreme Court's decision overturned Roe v. Wade, which said there was a federal constitutional right to abortion.
- Kacsmaryk's decision does not affect the availability of misoprostol, which the World Health Organization recommends as a standalone abortion drug.
- States such as California are stockpiling misoprostol if Kacsmaryk's decision goes into effect.
- Photo via Wikimedia Commons
- 據報道，在一份新的法庭文件中，美國23個州的民主黨總檢察長警告說，聯邦法官暫停美國食品藥品管理局對米非司酮的批准的決定 “對數百萬人構成了毀滅性風險”，其中包括墮胎仍然合法的州。
- 總檢察長在文件中呼籲美國第五巡迴上訴法院將米非司酮保留在市場上。
- 上週五，一名美國法官暫停了美國食品藥品管理局對米非司酮的批准，米非司酮是一種在妊娠十週之前終止妊娠的墮胎藥。
- 但他將決定擱置一週，以便讓拜登政府有時間提出上訴。
- 另請閱讀- 製藥商捍衛生殖權利：譴責暫停批准墮胎藥的300家中有輝瑞和Biogen。
- 如果第五巡迴法院不停止裁決，Kacsmaryk的裁決將在美國東部時間週六上午12點生效。
- CNBC援引該文件報道說，總檢察長和哥倫比亞特區譴責Kacsmaryk的裁決是 “法律錯誤的”，並警告說這將破壞FDA的批准程序。
- 總檢察長辯稱，卡斯馬雷克的命令將 “削弱各州爲保護墮胎機會而做出的主權決定”，而去年，最高法院的裁決推翻了羅伊訴韋德案，該案稱聯邦有墮胎的憲法權利。
- Kacsmaryk的決定並不影響米索前列醇的供應，世界衛生組織建議將米索前列醇作爲一種獨立的墮胎藥物。
- 如果卡斯馬雷克的決定生效，加利福尼亞州等州將儲存米索前列醇。
- 照片來自維基共享資源